Why would they need a lump sum of 30 million? They're not going to be paying everyone up front for the work that they would do in the next two years. They will need some money gradually over two years. It is unlikely that the share price will sit at this level for the next two years as clinical trial results come in -- any Aspire financing probably is not going to be down here. There are many interim clinical trial results that could come in, in the next few months. There are many other potential news items that could focus attention on this incredibly undervalued stock. It's being priced like a pre-clinical company when it has 5 clinical trials in progress -- ridiculous.

Also let's remember that the Rosen/Ashcroft meeting with the judge for sanctions it tomorrow.